There is some evidence to suggest that low-dose human chorionic gonadotropin (HCG) may have potential benefits for managing symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland enlarges and causes urinary symptoms. HCG is a hormone that is naturally produced in the body during pregnancy, but it can also stimulate the testes to produce testosterone and other hormones in men.
One study published in the Journal of Clinical Endocrinology and Metabolism in 2005 looked at the use of low-dose HCG (500 IU three times per week) in men with BPH who were not candidates for surgery. After six months of treatment, the men experienced significant improvements in their urinary symptoms, as well as increases in their prostate-specific antigen (PSA) levels and serum testosterone levels. The authors of the study suggested that the HCG treatment may have helped to shrink the prostate gland, improve bladder function, and reduce inflammation.
Another study published in the Journal of Andrology in 2012 evaluated the use of HCG as an alternative to standard medical therapies for BPH, such as alpha-blockers and 5-alpha reductase inhibitors. The study found that HCG treatment (500 IU every other day for 12 weeks) resulted in significant improvements in urinary symptoms and flow rates, as well as reductions in prostate volume and PSA levels.
While the use of low-dose HCG for BPH is not yet widely accepted as a standard treatment, these studies suggest that it may have potential benefits for some men. However, more research is needed to fully understand the risks and benefits of this approach, as well as the optimal dosing and duration of treatment. Men considering HCG treatment for BPH should discuss the potential risks and benefits with their healthcare provider.